Neurovance appoints ex-Shire lead as VP, clinical development
This article was originally published in Scrip
Neurovance, a clinical-stage neuroscience-focused company developing centanafadine SR for adult attention-deficit hyperactivity disorder (ADHA), has named Brigitte Robertson vice-president of clinical development. Dr Robertson, a board certified adult, child and adolescent psychiatrist, joins the Cambridge, Massachusetts-based company from Shire, where she was most recently global development strategy team lead. Shire, which is in the process of being acquired by AbbVie, manufactures Vyvanse, the leading ADHD franchise worldwide.